36289711|t|Activity of a Novel Anti-Inflammatory Agent F-3,6'-dithiopomalidomide as a Treatment for Traumatic Brain Injury.
36289711|a|Traumatic brain injury (TBI) is a major risk factor for several neurodegenerative disorders, including Parkinson's disease (PD) and Alzheimer's disease (AD). Neuroinflammation is a cause of later secondary cell death following TBI, has the potential to aggravate the initial impact, and provides a therapeutic target, albeit that has failed to translate into clinical trial success. Thalidomide-like compounds have neuroinflammation reduction properties across cellular and animal models of TBI and neurodegenerative disorders. They lower the generation of proinflammatory cytokines, particularly TNF-alpha which is pivotal in microglial cell activation. Unfortunately, thalidomide-like drugs possess adverse effects in humans before achieving anti-inflammatory drug levels. We developed F-3,6'-dithiopomalidomide (F-3,6'-DP) as a novel thalidomide-like compound to ameliorate inflammation. F-3,6'-DP binds to cereblon but does not efficiently trigger the degradation of the transcription factors (SALL4, Ikaros, and Aiolos) associated with the teratogenic and anti-proliferative responses of thalidomide-like drugs. We utilized a phenotypic drug discovery approach that employed cellular and animal models in the selection and development of F-3,6'-DP. F-3,6'-DP significantly mitigated LPS-induced inflammatory markers in RAW 264.7 cells, and lowered proinflammatory cytokine/chemokine levels in the plasma and brain of rats challenged with systemic LPS. We subsequently examined immunohistochemical, biochemical, and behavioral measures following controlled cortical impact (CCI) in mice, a model of moderate TBI known to induce inflammation. F-3,6'-DP decreased CCI-induced neuroinflammation, neuronal loss, and behavioral deficits when administered after TBI. F-3,6'-DP represents a novel class of thalidomide-like drugs that do not lower classical cereblon-associated transcription factors but retain anti-inflammatory actions and possess efficacy in the treatment of TBI and potentially longer-term neurodegenerative disorders.
36289711	24	43	-Inflammatory Agent	Chemical	-
36289711	44	69	F-3,6'-dithiopomalidomide	Chemical	-
36289711	89	111	Traumatic Brain Injury	Disease	MESH:D000070642
36289711	113	135	Traumatic brain injury	Disease	MESH:D000070642
36289711	137	140	TBI	Disease	MESH:D000070642
36289711	177	204	neurodegenerative disorders	Disease	MESH:D019636
36289711	216	235	Parkinson's disease	Disease	MESH:D010300
36289711	237	239	PD	Disease	MESH:D010300
36289711	245	264	Alzheimer's disease	Disease	MESH:D000544
36289711	266	268	AD	Disease	MESH:D000544
36289711	271	288	Neuroinflammation	Disease	MESH:D000090862
36289711	340	343	TBI	Disease	MESH:D000070642
36289711	496	507	Thalidomide	Chemical	MESH:D013792
36289711	528	545	neuroinflammation	Disease	MESH:D000090862
36289711	604	607	TBI	Disease	MESH:D000070642
36289711	612	639	neurodegenerative disorders	Disease	MESH:D019636
36289711	710	719	TNF-alpha	Gene	7124
36289711	783	794	thalidomide	Chemical	MESH:D013792
36289711	833	839	humans	Species	9606
36289711	862	874	inflammatory	Disease	MESH:D007249
36289711	901	926	F-3,6'-dithiopomalidomide	Chemical	-
36289711	928	937	F-3,6'-DP	Chemical	-
36289711	950	961	thalidomide	Chemical	MESH:D013792
36289711	990	1002	inflammation	Disease	MESH:D007249
36289711	1004	1013	F-3,6'-DP	Chemical	-
36289711	1023	1031	cereblon	Gene	58799
36289711	1111	1116	SALL4	Gene	99377
36289711	1118	1124	Ikaros	Gene	10320
36289711	1130	1136	Aiolos	Gene	22806
36289711	1206	1217	thalidomide	Chemical	MESH:D013792
36289711	1356	1365	F-3,6'-DP	Chemical	-
36289711	1367	1376	F-3,6'-DP	Chemical	-
36289711	1401	1404	LPS	Chemical	MESH:D008070
36289711	1413	1425	inflammatory	Disease	MESH:D007249
36289711	1437	1446	RAW 264.7	CellLine	CVCL:0493
36289711	1535	1539	rats	Species	10116
36289711	1565	1568	LPS	Chemical	MESH:D008070
36289711	1699	1703	mice	Species	10090
36289711	1725	1728	TBI	Disease	MESH:D000070642
36289711	1745	1757	inflammation	Disease	MESH:D007249
36289711	1759	1768	F-3,6'-DP	Chemical	-
36289711	1791	1808	neuroinflammation	Disease	MESH:D000090862
36289711	1810	1823	neuronal loss	Disease	MESH:D009410
36289711	1829	1848	behavioral deficits	Disease	MESH:D019958
36289711	1873	1876	TBI	Disease	MESH:D000070642
36289711	1878	1887	F-3,6'-DP	Chemical	-
36289711	1916	1927	thalidomide	Chemical	MESH:D013792
36289711	1967	1975	cereblon	Gene	58799
36289711	2025	2037	inflammatory	Disease	MESH:D007249
36289711	2087	2090	TBI	Disease	MESH:D000070642
36289711	2119	2146	neurodegenerative disorders	Disease	MESH:D019636
36289711	Negative_Correlation	MESH:D013792	MESH:D007249
36289711	Positive_Correlation	MESH:D008070	MESH:D007249
36289711	Negative_Correlation	MESH:D013792	MESH:D000090862
36289711	Negative_Correlation	MESH:D013792	7124
36289711	Negative_Correlation	MESH:D013792	MESH:D019636
36289711	Association	MESH:D013792	99377

